CDKN2A Interacting Protein Proteins (CDKN2AIP)

Human CDKN2A Interacting Protein (CDKN2AIP) interaction partners

1. a comprehensive current understanding into the molecular mechanisms of CARF functions in regulation of DNA damage response, cell cycle checkpoints, cell survival and death signaling pathways.

2. report that CARF (Collaborator of ARF) is a new target of miR-335 that regulates its growth suppressor function by complex crosstalk with other proteins including p16(INK4A), pRB, HDM2 and p21(WAF1)

3. Oncogenic functions of CARF in hepatocellular carcinoma tumorigenesis is a result of activation of beta-catenin/TCF signaling.

4. CARF promotes carcinogenesis in p53-deficient cells by repressing p21WAF1 and promoting cell cycle progression.

5. The results suggest that CARF regulates early steps of pre-rRNA processing during ribosome biogenesis by controlling spatial distribution of XRN2 between the nucleoplasm and nucleolus.

6. CARF regulates proliferative fate of human cells by dose-dependent regulation of DNA damage signaling.

7. Analysis of indel variations in the human disease-associated genes CDKN2AIP, WDR66, USP20 and OR7C2 in a Korean population.

8. CARF knockdown elicited DNA damage response as evidenced by increased levels of phosphorylated ATM and gammaH2AX, leading to induction of mitotic arrest and eventual apoptosis.

9. CARF may act as a novel key regulator of the p53 pathway at multiple checkpoints

10. cooperates with human p14ARF in activating p53

11. CARF may exert a vital control on p53-HDM2-p21(WAF1) pathway that is central to the cell cycle control, senescence, and DNA damage response of human cells

12. CARF exerts a vital control on the p53-HDM2-p21WAF1 pathway that is frequently altered in cancer cells.

13. CARF plays a dual role in regulating p53-mediated senescence and apoptosis, the two major tumor suppressor mechanisms.

Mouse (Murine) CDKN2A Interacting Protein (CDKN2AIP) interaction partners

1. Oncogenic functions of CARF in hepatocellular carcinoma tumorigenesis is a result of activation of beta-catenin/TCF signaling.

2. CARF may act as a novel key regulator of the p53 pathway at multiple checkpoints